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Before inserting a chest drain, individual doctors 
should always ask themselves:
• Do I need to do this? (The presence of a 
pneumothorax or pleural effusion does not 
automatically require insertion of a chest drain.)
• Does it need to be done as an emergency or can 
it wait? (There are few indications for chest drain 
insertion as an emergency “out of hours.”)
• Have I had enough training to feel confident to 
do this? Are senior staff to hand?
• Am I familiar with this equipment?
• Is ultrasound available, with trained staff, to 
enable me to position the drain safely?
And if something were to go wrong (for example, 
if no portable ultrasound machine is available on the 
ward) the doctor should always report this as a patient 
safety incident so that local action can be taken and 
others can learn.
What else do we need to know?
Queries from clinicians after the issue of the NPSA’s 
RRR highlighted further areas of uncertainty: compe-
tencies and training (such as the minimum number of 
procedures required before a clinician is safe to practise, 
and the use of manikins for simulation); relative safety 
and effectiveness of different techniques (small versus 
large bore drains; Seldinger technique versus blunt dis-
section); appropriate use of thoracic ultrasonography 
and, if this is performed by physicians, the minimum 
amount of training required.4 These areas of uncertainty 
will be clarified by the British Thoracic Society, which 
is currently updating its guidelines on  pleural proce-
dures  and has also published guidance to help clinicians 
implement the recommendation in the RRR.5
How will we know when practice has become safer?
No national baseline data on pleural procedures are 
available, but in a survey of 99 UK trusts in 2008, two 
thirds had encountered major complications associated 
with chest drain insertion (including 17 deaths) in the pre-
ceding five years, suggesting higher rates of harm than 
indicated by incident reporting. Only 11 trusts had a 
formal training policy for chest drain insertion, and only 
a fifth routinely sought written patient consent. Chest 
drains were commonly inserted by junior trainees.6  
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Why read this summary?
Chest drains are often used in the medical management 
of pleural effusions and pneumothorax. However, the 
real risks of chest drains are not fully recognised.1 Over 
three years ( January 2005 to March 2008) healthcare 
staff reported 12 deaths and 15 cases of severe harm 
from chest drain insertion to the National Patient Safety 
Agency (NPSA) in England and Wales. True rates of 
harm to patients are likely to be substantially higher, 
given that healthcare staff are known to under-report 
incidents (as is the case with other voluntary reporting 
systems).2
Incidents were reported to the agency from a range 
of settings, including general wards, accident and emer-
gency departments, medical admission units, and inten-
sive care. A typical incident report reads: “Right-sided 
chest drain inserted into patient. Couldn’t find com-
plete chest drain kit on ward. Tip of drain seen within 
right lobe of liver. No record of ultrasound performed. 
Liver injury incurred and patient sent to ITU [intensive 
therapy unit].”
This summary is based on a safety report (known as 
a “rapid response report” or “RRR”) from the NPSA 
on the risks of chest drain insertion, with key actions 
for staff. 
Problems identified by the National Patient Safety 
Agency
Problems included:
• Poor selection of site for drain insertion and 
without use of ultrasonography
• Inadequate supervision of trainee doctors
• Equipment problems, including lack of familiarity 
with different kits (many types used in a single 
trust) and excessive length of available dilators
• Lack of awareness of national clinical guidelines.3
In May 2008 the NPSA issued its RRR on the risks 
of chest drain insertion (NPSA/2008/RRR03, www.
nrls.npsa.nhs.uk/resources/?entryid45=59887).
What can we do?
In the 2008 RRR, the NPSA asked each hospital to 
take actions including identifying a lead for training 
and making ultrasound machines available on wards 
to guide insertion.
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Since the RRR was issued, 74% of trusts in England 
have reported that they had complied with the recom-
mended actions.7 Monitoring continues, and since the 
issue of the 2008 RRR, and up to mid-November 2009, 
the NPSA has received seven reports of patients with 
organ perforations after drain insertion, including two 
deaths (which are being investigated by trusts).
The British Thoracic Society (with input from the 
NPSA) conducted a pilot audit of pleural procedures in 
12 trusts in England (serving a collective population of 
about five million) in 2009. Early analysis showed that 
over two thirds of these trusts had acted on key RRR 
recommendations, such as identifying a pleural lead 
and ensuring active training, supervision, and increased 
access to bedside ultrasonography.8 A snapshot audit 
(insertion of 112 chest drains during July 2009) at these 
12 trusts indicated that bedside ultrasonography was 
available in over half of the procedures but that patient 
consent was only recorded in two fifths. Complications 
were recorded as one case of self limiting bleeding and 
two cases of iatrogenic infection. These encouraging 
initial findings show that trusts are taking real steps 
to improve safety, as well as highlighting areas where 
more work is needed (such as patient consent and infec-
tion). The British Thoracic Society plans to roll out an 
audit across the UK of pleural procedures next year to 
collect further data on current practice.
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Four weeks ago (BMJ 2009;339:b3862) we described 
the case of 23 year old Andrea G, who presented with 
progressive transverse spinal cord syndrome in early 
pregnancy. Her symptoms recurred during a subse-
quent pregnancy (BMJ 2009;339:b4025). 
We considered many possible causes, including 
autoimmune inflammatory disorders such as multiple 
sclerosis or systemic lupus erythematosus and acute 
rubella infection, but these were excluded by the 
combination of clinical presentation and the results 
of laboratory tests or magnetic resonance imaging 
(MRI). Since the most striking feature was the verti-
cal extension of the spinal cord lesion on MRI, we 
considered recurrent relapses of longitudinally exten-
sive transverse myelitis to be the most likely diagnosis. 
This condition is characterised by transverse myelitis 
with spinal cord lesions extending over three or more 
vertebral segments.1 Tests showed anti-aquaporin 4 
(AQP4) antibodies in our patient’s serum, confirming 
the diagnosis.2 Oligoclonal bands were not detected. 
These are often present in patients with central nerv-
ous system infection or autoimmune disease, includ-
ing 85-95% of those with multiple sclerosis but only 
15-30% of patients with longitudinally extensive trans-
verse myelitis.
We treated Mrs G with eight courses of plasma 
exchange. Her clinical symptoms improved immedi-
ately, and her spinal cord lesions had reduced in size 
on subsequent MRI scans. Plasma exchange, alongside 
intravenous immunoglobulin, is also effective in other 
immune system mediated disorders such as Guillain-
Barré syndrome and myasthenia gravis.
In the 21st week of her second pregnancy Mrs G 
had a spontaneous miscarriage. Macroscopically and 
microscopically the fetus was normal. Histological 
investigation of the placenta showed multiple infarcts 
mainly located in the maternal part of the placenta. 
AQP4 immunostaining showed a complete loss of 
immunoreactivity. In a normal placenta AQP4 is 
expressed in specific cell types depending on the stage 
of pregnancy.3 In addition, diffuse, mainly perivascu-
lar, deposits of membrane attack complexes of the 
complement system were clearly detectable in the 
 syncytiotrophoblasts and to a moderate degree in the 
This is the final part of a three 
part case report that describes 
the outcome and summarises 
the comments made by readers 
during the presentation of a real 
patient’s story. Further responses 
are welcome through bmj.com
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perivasal layers of the fetal vessels (figure).
The fact that Mrs G experienced both episodes 
during pregnancy suggests a pathogenic relevance of 
immunological changes during gestation in the devel-
opment of her condition and points to an increased 
risk of relapse in pregnancy. Animal studies showed an 
up-regulation of AQP4 in the central nervous system 
during mid-pregnancy.4 An up-regulation of AQP4, 
together with a shift in the mediator of the immune 
response from T helper cell 1 to T helper cell 2 during 
pregnancy, may have led to increased antigen stimula-
tion and subsequent production of antibodies to AQP4 
Diffuse, mainly perivascular deposits (red staining) of 
the membrane attack complex of the complement system 
detected with an antibody to the C9neo epitope. Fetal 
vessels show moderate markings (A) and the phagocytic 
syncytiotrophoblast (a crucial interface for maternal-fetal 
placental transfer processes) is clearly marked (B)
in our patient. We therefore believe that increased anti-
body production may have been responsible for both 
the myelitis and the miscarriage. 
During the next seven months, Mrs G’s myelitis 
recurred four times, including a first instance of opti-
cal neuritis in July 2007. This  led to the diagnosis of 
neuromyelitis optica, for which longitudinal extensive 
transverse myelitis is often a precursor. 
Because of the likely association with pregnancy and 
repeated relapses, Mrs G had no desire to become 
pregnant again immediately. In August 2007 she began 
off-label immunosuppressive treatment with rituximab 
(2×1 g administered intravenously), an anti-CD20 anti-
body that depletes B cells.5 This stabilised her condi-
tion, and she had no further relapses until May 2008. 
She was given a second cycle of rituximab at the end 
of May. In October 2008, no CD19 or CD20 positive 
cells were detected in her peripheral blood, and she 
remains well. 
We thank W Brück for the figure, C F lucchinetti for aquaporin 4 
immunostaining, and M Vieth for discussion of placental pathology.
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As a medical educationalist and part time general 
practitioner, I was comfortable reading the first three 
paragraphs of this case presentation,1 couched in famil-
iar descriptors of a patient’s signs and symptoms. My 
attention was caught by the issues of the termination 
choices that Andrea G faced. Initially, the unusual fea-
tures of her case engaged the amateur clinical detec-
tive within me. It soon became apparent, however, 
that most of this case presentation was a description of 
clinical events and diagnostic and management dilem-
mas that are outside my competence, my experience, 
and certainly any learning needs that I had identified 
for myself.
Was it a waste of time to proceed? With learning 
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time so precious, and so much that we need to know 
but don’t, many would argue that the responsible pro-
fessional course is to become discriminatory in our 
allocation of learning time. But what about “spin-off” 
learning? Should we be balancing learning aimed at 
remedying the known and directly relevant deficits in 
our knowledge and skills with exploration of clinical 
material outside our comfort zone?
Phrases such as “targeted learning” are often men-
tioned in response to time pressures in the clinical 
environment. Slotnik describes the stages that clini-
cians go through to answer the specific questions that 
arise in their clinical practice.2 There can seem to be 
a straight line relation between identifying learning 
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Most pregnant women are not sick and access hospitals 
only for interaction with midwives and obstetricians, 
usually for pregnancy specific care. This case describes 
the opposite end of the spectrum and shows many of 
the challenges faced by a woman and her doctors when 
there may be conflict between optimal investigation and 
management of a medical problem and minimisation 
of risks to the fetus.1
The use of appropriate imaging is essential to avoid 
unnecessary morbidity and mortality in pregnancy. 
The triennial confidential inquiry into maternal deaths 
highlighted delays in diagnosis of pulmonary embolic 
events arising from doctors’ reluctance to arrange appro-
priate imaging, often because of misjudged concerns 
about fetal safety.2 However, when such imaging occurs, 
it is essential that a woman has access to appropriate 
information, including a risk assessment provided by 
a medical physicist to guide her decisions. This is par-
ticularly important if the decisions include whether to 
continue or terminate the pregnancy. A recent review 
on the risks of diagnostic radiation exposures estimated 
that 8% of those who contacted the pregnancy website 
of the Health Physics Society were provided with inac-
curate information that could have led to unnecessary 
termination of pregnancy.3
The aetiology of the second pregnancy loss in this case 
is unclear, with the importance of the multiple placental 
infarcts and loss of aquaporin 4 immunoreactivity uncer-
tain. The interplay between diseases of autoimmune 
origin and pregnancy is complex and often specific to 
each condition—for example, there is improvement of 
symptoms in most women with rheumatoid arthritis, 
while pregnancy increases the likelihood of flares in sys-
temic lupus erythematosus.4 Of relevance to this case, 
meta-analysis has shown increased unadjusted odds of 
preterm birth (odds ratio 1.36, 95% confidence interval 
1.24 to 1.50), and hence potentially mid-trimester mis-
carriage, with previous termination of pregnancy.5
Pre-pregnancy counselling is essential for such women 
and requires multidisciplinary input from neurologists in 
collaboration with maternal-fetal medicine subspecialists 
or obstetric physicians; it should include consideration 
of the effect of pregnancy on the disease, the effect of 
the disease on pregnancy; and possible management 
strategies, which may be limited by potential teratogenic 
drug effects. The rarity of longitudinally extensive trans-
verse myelitis and the additional complexity of Andrea’s 
obstetric history make such counselling difficult.
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needs and meeting them—fitting with continuity theo-
ries of learning.3 But perhaps this is not how junior 
doctors learn most effectively in the turbulent clinical 
environment. A recent study on clerkships found no 
relation between learning strategies and clinical per-
formance.4 The authors suggest that this reflects the 
complexity of clinical learning.
Learning is complex. In order to understand bet-
ter the breadth of learning, we may have to invoke 
discontinuity.3 This may be shown by recent work on 
how babies learn.5 Their effective, if random and unfo-
cused, approaches to learning would be difficult to 
explain by direct causal lines. Perhaps this is a model 
of learning out of your depth: after all babies can be 
surprising swimmers.
Back to the case of Andrea G. Even without appre-
ciating the finer detail apparent to specialists, I learnt 
a lot about myelopathy, myelitis, immunotherapy, and 
plasma exchange. Who knows when this extended 
conceptual understanding may not prove useful to 
me or my patients, even though I doubt I will encoun-
ter a very rare case like this? What is more, the real 
patient experience of Mrs G will inevitably broaden 
my horizons. I am not alone: the rapid responses on 
bmj.com showed that others at different professional 
stages engaged in learning from the complexity of this 
unusual case.
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When Mrs G presented to the emergency room, clini-
cal examination with transverse spinal cord syndrome, 
magnetic resonance imaging, and her complete clini-
cal remission after plasmapheresis as well as lack of 
response to treatment pointed to longitudinally exten-
sive transverse myelitis, representing an inaugural or 
limited form of neuromyelitis optica. The diagnosis 
was confirmed by detection of anti-aquaporin 4 (AQP4) 
antibodies.
In the rapid responses Mike Boggild states that a 
variety of other autoantibodies are often seen within 
the spectrum of neuromyelitis optica disorders.1 Con-
versely, several cases of pregnancy related myelitis asso-
ciated with lupus erythematosus have been reported. 
Some of them might have been misclassified as lupus 
because the patient had raised antinuclear antibody 
titres.
As Muhammad K Rafiq points out, autoimmune con-
ditions tend to deteriorate in pregnancy, which seems 
to apply to longitudinally extensive transverse myelitis.1 
Yet, this is not true for multiple sclerosis, which improves 
clinically during pregnancy, suggesting the diseases have 
different autoimmune pathomechanisms.
A very intriguing and new facet of our present case 
is the similarity of histological lesions in the spinal cord 
of patients with neuromyelitis optica2 and our patient’s 
placenta—that is, complete disappearance of aquaporin 
4 immunoreactivity and presence of activated comple-
ment deposits. The observed infarcts in the placenta 
may be a consequence of these complement deposits, 
which might have led to the miscarriage. Microinfarcts 
are a hallmark of lesions in neuromyelitis optica and 
longitudinally extensive transverse myelitis. AQP4 anti-
bodies may have a role in the development of repeated 
miscarriage. No reason has been found for about half of 
such cases, although immunological causes have been 
suggested.3 
In general, one acute treatment option of autoim-
mune diseases such as anti-D antibody conflict or 
HELLP syndrome (haemolysis, elevated liver enzymes, 
and low platelet count) during pregnancy is plasmapher-
esis. Without treatment, future pregnancy in our patient 
seems likely to risk exacerbation of n euromyelitis optica 
and a complicated disease course.
Although prophylactic treatment with rituximab 
might prevent problems in pregnancy, current data sug-
gest the drug should not be used during pregnancy.4 A 
few cases of use of rituximab during pregnancy have 
been published. A temporary suppression of the devel-
opment of B cells in the fetus has been observed.5 In 
one case the in vitro fertilisation of a woman with anti-
cardiolipin antibodies was successful only after previous 
treatment with rituximab.6 Thus, if Mrs G should wish 
to become pregnant again, rituximab might increase 
the chance of a more favourable course.
Mrs G’s case shows that a result acceptable to the 
patient could be achieved and appears to be achiev-
able in the future only as a result of interdisciplinary 
diagnostics and treatment.
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Andrea G, with the support of Reinhard Reuß
In March 2006 I was in the prime of life, happily in love, 
and 14 weeks pregnant, and the last thing I expected 
was that this would suddenly be snatched from me. I 
started to get pain in the area around the upper part of 
my back. Within a few weeks I found myself unable to 
walk. I couldn’t understand what was going on. How 
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could my condition have worsened so drastically? What 
if treatment didn’t work?
I was appalled by the results of my magnetic reso-
nance imaging. Even though I worked in a medical 
profession, I could not come to terms with them. 
I had a lot of support from my family, my friends, 
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and my partner at that time, which gave me a lot of 
strength. At the age of 22, I didn’t want to be looking 
at the world from a wheelchair. That’s why I kept on 
 fighting.
The second attack happened when I was seven 
weeks pregnant. Once again I had this tingling and 
everyone said, “You’re imagining things because 
you’re afraid.” But then everything began to change 
at an alarming rate.
I didn’t find it quite as bad this time—I’m not really 
sure why, but probably because I knew that nothing 
could happen to the baby as a result of the plasma 
exchange and nothing else would help. And the last 
time everything had sorted itself out.
I was 20 weeks pregnant when my waters broke 
early and I lost the baby. I thought my world had 
fallen apart. Two weeks later I was made redundant, 
which was another slap in the face.
At this point I was in deep despair. I still had no 
exact diagnosis, was 80% disabled, unemployed, had 
lost two children, and felt like I was on the scrapheap 
at the age of 23. What is there left to shock you?
I was still having relapses, and then in the summer 
of 2007 I had two within the space of three weeks. 
I had no time to recover, and even my eyes were 
affected—it was ghastly. The doctors were worried and 
advised me to have treatment with rituximab. What 
else could I do, even though I had previously resisted 
going down this route? 
Today, I can say that it was a good decision. I’ve 
already received two units: after the first one I went 
nine months without a relapse, and I’m hoping that 
after the second dose I will go even longer without a 
relapse.
And so my life has changed dramatically. I have 
become stronger, and I know—no matter how hard 
things may be for me in future—there are people who 
are there for me. I will never give up the fight.
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As suggested by this case report,1 many neurological 
disorders are affected by pregnancy.2 These include 
common and benign conditions such as migraine, 
Bell’s palsy, carpal tunnel syndrome, and other periph-
eral neuropathies. The reason pregnancy modifies 
neurological disease may be alterations in the vas-
cular and immune systems, which are influenced by 
the endocrine environment. The vascular disturbances 
include increased vascular volume and hypercoagula-
bility. The immune changes include a shift from Th1 
to Th2 lymphocytes. These changes exacerbate cer-
tain disorders and relieve others.
longitudinally extensive myelopathies
Longitudinally extensive myelopathy, defined as spinal 
cord disease spanning three or more contiguous spi-
nal segments,3 4 has a broad differential diagnosis (see 
table on bmj.com). Longitudinally extensive transverse 
myelitis is one type, and specifically refers to conditions 
with inflammation of the spinal cord. Identification of 
the cause of longitudinally extensive transverse myelitis 
relies on the clinical presentation, ancillary diagnostic 
tests (such as cerebrospinal fluid analysis) and spinal 
magnetic resonance imaging (MRI). In inflammatory 
and neoplastic conditions, for example, MRI typically 
shows cord enlargement and contrast enhancement. 
Andrea G was diagnosed with neuromyelitis optica, 
which is now recognised as a distinct category of longi-
tudinally extensive transverse myelitis, although debate 
remains as to its pathophysiological relation with mul-
tiple sclerosis.
Neuromyelitis optica is a potentially devastating dis-
ease, producing blindness, quadriplegia, respiratory 
collapse, and death. Early recognition and subsequent 
treatment offer hope for clinical stability and improve-
ment. The full clinical syndrome includes longitudi-
nally extensive transverse myelitis and bilateral optic 
 neuropathy, but antibody confirmed disease can pro-
duce a spectrum of clinical presentations.4 Currently, the 
diagnosis rests on antibody confirmation in patients with 
myelopathy or optic neuropathy. The antibody targets 
the aquaporin 4 protein, a transmembrane water chan-
nel that is increasingly implicated in other diseases such 
as cerebral oedema and eclampsia.
Neuromyelitis optica should be suspected in any 
patient with longitudinally extensive myelopathy, severe 
unilateral optic neuritis (no light perception), poor 
recovery from unilateral optic neuritis, or bilateral optic 
neuritis. Antibody testing need not await the full clini-
cal syndrome (myelitis and bilateral optic neuropathy). 
Treatments such as corticosteroids or plasmapheresis 
should be started early. The use of immunomodulatory 
drugs, such as rituximab, has been recommended.5
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